Ra Medical Systems to Present at Biotech Showcase 2019 on January 8 during Annual JPMorgan Healthcare Conference in San Francisco

CARLSBAD, Calif.–(BUSINESS WIRE)–Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser systems to treat tough vascular and dermatological diseases, announces that CEO Dean Irwin will present at the 11^th Annual Biotech Showcase on January 8, 2019, in San Francisco.

Mr. Irwin will present an overview of Ra Medical’s business, technology and strategic growth objectives, including the commercialization of its excimer laser system, DABRA™, which is FDA-cleared to cross chronic total occlusions in patients with symptomatic infrainguinal lower extremity vascular disease. DABRA is engineered to photochemically ablate, or dissolve, plaque build-up in the arteries, thereby minimizing downstream debris and creating a channel for blood to flow. Mr. Irwin will also discuss Ra Medical’s plans to evaluate the potential for DABRA to treat lesions in coronary vessels.

A live webcast and replay of the presentation will be available on the Investors section of the Company’s website, https://ir.ramed.com/ir-calendar.

Ra Medical’s presentation will take place in the Yosemite C room on the Ballroom Level of the Hilton San Francisco at 2:30 p.m. PT on Tuesday, January 8, 2019. Mr. Irwin will be available to participate in one-on-one meetings with members of the financial and media communities. To schedule a meeting, contact LHA Investor Relations at 310-691-7100.

About Biotech Showcase

The largest international biotech investor conference in the world, Biotech Showcase brings together life sciences decision-makers and investors from across the globe to collaborate and discuss industry trends through panels, workshops and fireside chats. Additional information and registration can be found here: https://ebdgroup.knect365.com/biotech-showcase/.

About Ra Medical Systems

Ra Medical Systems commercializes excimer lasers and catheters for the treatment of dermatological and vascular diseases. In May 2017, DABRA laser system and disposable DABRA catheter received FDA 510(k) clearance in the U.S. for the intended use of ablating a channel in occlusive peripheral vascular disease. Pharos excimer laser system is FDA-cleared and is used as a tool in the treatment of psoriasis, vitiligo, atopic dermatitis, and leukoderma. DABRA and Pharos are both based on Ra Medical’s core excimer laser technology platform and deploy similar mechanisms of action. Independent in vivo and in vitro research studies have demonstrated that 308 nanometer excimer laser light, which is the same wavelength used in DABRA and Pharos, increases T-cell apoptosis, or cell death, which may produce an immunosuppressive effect. We manufacture our DABRA and Pharos excimer lasers and catheters in our approximately 32,000-square-foot facility located in Carlsbad, California. Our vertically integrated facility is ISO 13485 certified and is licensed by the state of California to manufacture our sterile, single-use catheters in our controlled environments.